Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 81 clinical trials
featured
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved

  • 1004 views
  • 23 Nov, 2020
  • 1 location
featured
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF) SOCRATES-PRESERVED

A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF) SOCRATES-PRESERVED

  • 522 views
  • 08 Nov, 2020
  • 1 location
Study of Verinurad in Heart Failure With Preserved Ejection Fraction

International, Multicenter, Double-Blind, 3-Arm, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection

  • 0 views
  • 10 Jan, 2021
  • 72 locations
CCM in Heart Failure With Preserved Ejection Fraction

This pilot study will evaluate the efficacy and safety of CCM therapy in heart failure patients with baseline EF50% (HFpEF) who have New York Heart Association (NYHA) Class II or III symptoms despite appropriate medication. The terminology of the HF classification HFpEF is based on the 2016 European Society of …

nt-probnp
heart failure with preserved ejection fraction
medical therapy
crescendo
ejection fraction
  • 52 views
  • 10 Sep, 2020
  • 40 locations
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With

spironolactone
n-terminal pro-bnp
natriuretic peptide
b-type natriuretic peptide
pro-brain natriuretic peptide
  • 46 views
  • 06 Jan, 2020
  • 119 locations
Changes in NT-proBNP and Outcomes Safety and Tolerability in HFpEF Patients With Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization and Initiated In-hospital or Within 30 Days Post-discharge (PARAGLIDE-HF)

The purpose of this study is to assess the effect of sacubitril/valsartan (LCZ696) vs. valsartan on changes in NT-proBNP and outcomes, safety and tolerability in patients with HFpEF (left ventricular ejection fraction (LVEF) > 40%) who have been stabilized during hospitalization for acute decompensated heart failure and initiated in-hospital or …

  • 27 views
  • 14 Jan, 2021
  • 81 locations
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure …

diuretics
diuretic therapy
hypertrophy
ventricular hypertrophy
  • 230 views
  • 31 Dec, 2020
  • 417 locations
Autonomic Regulation Therapy in Heart Failure With Preserved Ejection Fraction

The ANTHEM-HFpEF Study is designed to demonstrate the safety and efficacy of vagus nerve stimulation (VNS) with the Cyberonics VNS Therapy System for the treatment of subjects with symptomatic heart failure with preserved and mid-range ejection fraction.

heart failure with preserved ejection fraction
ejection fraction
  • 13 views
  • 08 Nov, 2020
  • 1 location
Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction

The global objective of this study is to determine the mechanisms of exercise intolerance and dyspnea on exertion (DOE) in patients with HFpEF and based on this pathophysiology, test whether specific exercise training programs (whole body vs single leg) will result in improved exercise tolerance.

diastolic dysfunction
dyspnea
heart failure with preserved ejection fraction
ejection fraction
  • 0 views
  • 24 May, 2020
  • 1 location
Abnormal Vascular Metabolic and Neural Function During Exercise in Heart Failure With Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of the heart failure population in the United States. The primary chronic symptom in patients with HFpEF is

left ventricular end-diastolic pressure
orthopnea
dyspnea
diastolic dysfunction
edema
  • 6 views
  • 12 Aug, 2020
  • 1 location